drugset / Trial / NCT00723346

Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia

NCT00723346

Phase 1/2 Completed 25 enrolled ERYtech Pharma Centre Leon Berard · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Primary objective : * To explore the relation between 3 doses of GRASPA and duration of asparagine depletion (\< 2µmol/l) Secondary objective : * Pharmacokinetic / Pharmacodynamic parameters * toxicity * Study duration : 2 years * Study treatment : Red blood cells loaded with L asparaginase versus native L asparaginase * Associated treatments : COPRALL chemotherapy * Randomization : centralised randomisation on scratching list

Timeline

Start
2006-01
Primary completion
2008-08
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject GRASPA Protein / enzyme biologic 50 iu/kg
Subject GRASPA Protein / enzyme biologic 100 iu/kg
Subject GRASPA Protein / enzyme biologic 150 iu/kg
Comparator native L asparaginase Unknown 10000 iu